Wall Street Cool On Claritin Defense: Schering Prepares For Desloratadine
Executive Summary
Schering-Plough's expected fourth quarter launch of desloratadine may serve as the next marker in Wall Street's assessment of patent defense strategies for the pharmaceutical industry.
You may also be interested in...
Pharmacia Could See Double COX-2 NME Drug Approvals In 2001
Pharmacia could gain approval of two COX-2 inhibitor drugs that are new molecular entities by late 2001.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011